<DOC>
	<DOCNO>NCT00899171</DOCNO>
	<brief_summary>RATIONALE : Studying sample bone marrow blood laboratory patient cancer may help doctor learn change occur DNA identify biomarkers related cancer . PURPOSE : This research study look bone marrow blood sample patient acute myeloid leukemia .</brief_summary>
	<brief_title>S9031-S9126-S9333-S9500-A , Studying Bone Marrow Blood Samples From Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - To determine whether expression previously identify acute myeloid leukemia ( AML ) -specific age-associated gene prognostic significance adult patient AML . - To examine , preliminarily , AML-specific age-associated expression change occur primitive hematopoietic leukemia blast ( i.e. , CD34+/38- ) . - To examine , preliminarily , whether methylation histone modification IRF8 CPG island/promoter region correlate IRF8 gene expression AML . OUTLINE : This multicenter study . Previously collect specimen RNA pre-treatment marrow peripheral blood obtain repository SWOG clinical trial ( SWOG-S9031 , SWOG-9126 , SWOG-9333 , SWOG-9500 ) . Samples analyze absolute expression level 23 select gene relative expression level splice variant via quantitative RT/PCR GeneScan assay link clinical outcome data main SWOG database . Samples subset patient analyzed confirm aberrant expression acute myeloid leukemia-specific age-associated gene highly enrich population leukemic blast ( CD34+/CD38- CD34+/CD38+ ) . DNA sample also analyze correlation IRF8 gene expression methylation histone modification IRF8 CPG island/promoter region .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pretreatment RNA specimens* available patient acute myeloid leukemia ( AML ) register frontline therapy follow clinical trial : SWOG9031 SWOG9126 SWOG9333 SWOG9500 Cryopreserved pretreatment cell specimens* available subset patient ( obtained complete response [ CR ] remain CR without relapse â‰¥ 2 year vs resistant disease [ i.e. , fail achieve CR evidence persistent AML follow induction therapy ] ) NOTE : All specimen currently available Southwest Oncology Group Myeloid Leukemia MDS Repository University New Mexico PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
</DOC>